Medifast (NYSE:MED) Releases Q1 2025 Earnings Guidance

Medifast (NYSE:MED) updated its first quarter 2025 earnings guidance on Tuesday. The company provided EPS guidance of -0.500-0.000 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Analysts Set New Price Targets

Separately, DA Davidson upgraded shares of Medifast from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $16.50 to $17.00 in a research report on Tuesday, November 5th.

Medifast Price Performance

MED stock opened at $16.05 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 3.11 and a debt-to-equity ratio of 0.06. The firm has a market cap of $175.59 million, a price-to-earnings ratio of 24.32 and a beta of 1.14. The company’s fifty day simple moving average is $16.61 and its 200 day simple moving average is $18.05. Medifast has a 12-month low of $14.76 and a 12-month high of $49.90.

Medifast (NYSE:MED) last announced its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.26. Medifast had a return on equity of 15.98% and a net margin of 1.09%. On average, analysts expect that Medifast will post 1.68 earnings per share for the current year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.